Adult and pediatric acute respiratory distress syndromes are severe forms of acute hypoxemic respiratory failure with high mortality rates. Recent reviews examine how Toll-like receptors bridge external infections and internal cellular injuries to drive lung inflammation, though targeted drug therapies have not yet transitioned into clinical practice.
Defining Acute Respiratory Distress Across Age Groups
Acute respiratory distress syndrome in adults, known as ARDS, and in children, designated as PARDS, represent severe and life-threatening forms of acute hypoxemic respiratory failure. These conditions arise from non-cardiogenic pulmonary edema. Mortality rates remain high, varying with illness severity, geographic location, and ventilation strategy. Studies show adult mortality ranges from 35–52%, while pediatric mortality spans 15–40%. The overall risk of death increases with age, though reported mortality peaks appear at both ends of the age spectrum. Survivors frequently experience physical, cognitive, and psychological impairments that add a substantial long-term morbidity and healthcare burden.
Diagnostic criteria differ between adults and children to address age-related factors. The Berlin definition established adult ARDS guidelines in 2012, emphasizing PaO2/FiO2 ratios, bilateral infiltrates, and the exclusion of cardiac causes of hypoxemia. Meanwhile, the Pediatric Acute Lung Injury Consensus Conference provided pediatric-specific criteria in 2015. This pediatric framework relies on radiographic evidence of parenchymal lung disease without requiring bilateral infiltrates. It favors the oxygenation index over the PaO2/FiO2 ratio to accommodate varied ventilation modes and oxygen saturation-based indices when arterial blood gas availability is limited.
Pathogenesis and the Breakdown of the Alveolar-Capillary Barrier
The central tenet of disease pathogenesis involves the breakdown of the alveolar-capillary barrier. This disruption leads to increased vascular permeability, alveolar flooding, hypoxemia, and eventual respiratory failure. Injuries drive this breakdown across both pulmonary endothelium and alveolar epithelium, alongside leukocyte infiltration, platelet aggregation, microvascular thrombosis, and fibrin deposition. Endothelial dysfunction, which includes inflammation and the disruption of cell junctions, further increases vascular leakage and cell death. This creates a self-amplifying immune response that fuels ongoing lung injury.
Triggers for these syndromes include direct and indirect events such as sepsis, pneumonia, trauma, or transfusion. These clinical triggers activate innate immunity via pattern recognition receptors, specifically Toll-like receptors. These receptors sense both pathogen-associated molecular patterns—including bacterial lipopolysaccharide, viral RNA, and fungal components—and damage-associated molecular patterns, such as high mobility group box 1 protein, heat shock proteins, mitochondrial DNA, and extracellular ATP.
The Role of Toll-like Receptors in Bridging Infection and Injury
By sensing both external infections and internal cellular injuries, Toll-like receptors regulate immune activation in the lungs. They bridge external insults to internal inflammatory responses, positioning them as essential upstream inflammatory sensors in both infectious and sterile lung injuries. When pathogen-associated molecular patterns enter the alveolar space in healthy lungs, Toll-like receptors recognize them and trigger downstream inflammatory cascades.
This recognition releases cytokines such as interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, CCL2, and interferon-beta. Many of these cytokines recruit neutrophils and monocytes to the site of injury. These inflammatory mediators then disrupt the alveolar-endothelial barrier by injuring epithelial cells and pulmonary capillary endothelial cells. The resulting barrier disruption increases vascular permeability, allowing protein-rich fluid and immune cells to flood the alveolar space.
Evolution of Supportive Care and Epidemiological Insights
Global incidence and management variability are detailed through epidemiological projects such as the LUNG SAFE study in adults and the PARDIE investigation in pediatrics. Alongside these epidemiological efforts, supportive non-pharmacological therapies have altered clinical management. Interventions such as low tidal volume ventilation, prone positioning, and conservative fluid strategies have successfully reduced mortality and morbidity.
Historically, the condition was originally described in 1967, prompting decades of progress in understanding the pathogenesis and pathophysiology of acute lung injury. Early diagnostic criteria evolved from observations of rapidly progressive respiratory failure requiring mechanical ventilation. A 4-point scoring system introduced in 1988 provided a quantitative assessment of lung injury severity based on hypoxemia, positive end-expiratory pressure, static respiratory compliance, and radiographic infiltrates. Simplified criteria followed in 1994, establishing arterial hypoxemia thresholds with PaO2/FiO2 ratios below 300 mmHg for acute lung injury and below 200 mmHg for ARDS.
Translational Challenges and Future Therapeutic Development
Despite a robust body of laboratory investigations and preclinical insights, translating cell and animal studies into effective pharmacological therapies has proven exceptionally challenging. There is currently no targeted drug therapy proven to consistently lower mortality in ARDS. While studies on innate immunity have targeted upstream inflammatory sensors like Toll-like receptors, TLR-directed therapies have yet transitioned into clinical practice.
This gap highlights the pressing need for more translational research, particularly regarding developmental distinctions and immune response variations by age. Knowledge gaps remain especially prominent in pediatric acute respiratory distress syndrome, where most supportive therapies are adapted directly from adult studies despite clear differences in disease progression. Future clinical progress depends on developing novel therapeutics that can facilitate and enhance lung repair, bridging the divide between laboratory discoveries and bedside treatments.
